Livforsakringsbolaget Skandia’s AbbVie ABBV Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33.8M	Buy	155,470 +18,500	+14%	+$4.1M	1.31%	13
2025 Q4	$31.3M	Sell	136,970 -800	-0.6%	-$182K	1.22%	13
2025 Q3	$31.9M	Buy	137,770 +8,200	+6%	+$1.67M	1.25%	11
2025 Q2	$24M	Buy	129,570 +20,500	+19%	+$3.81M	1.05%	14
2025 Q1	$22.9M	Sell	109,070 -600	-0.5%	-$117K	1.29%	10
2024 Q4	$19.5M	Sell	109,670 -300	-0.3%	-$55.2K	1.03%	15
2024 Q3	$21.7M	Buy	109,970 +33,785	+44%	+$6.31M	1.17%	13
2024 Q2	$13.1M	Buy	76,185 +1,644	+2%	+$272K	1.07%	16
2024 Q1	$13.6M	Buy	74,541 +6,100	+9%	+$1.05M	1.15%	14
2023 Q4	$10.6M	Buy	68,441 +1,769	+3%	+$258K	1.01%	15
2023 Q3	$9.94M	Sell	66,672 -3,000	-4%	-$440K	1.09%	14
2023 Q2	$9.38M	Sell	69,672 -6,900	-9%	-$1.01M	0.97%	16
2023 Q1	$12.2M	Hold	76,572	–	–	1.28%	11
2022 Q4	$12.4M	Sell	76,572 -96	-0.1%	-$14.7K	1.42%	11
2022 Q3	$10.3M	Sell	76,668 -20,900	-21%	-$3M	1.27%	12
2022 Q2	$14.9M	Sell	97,568 -6,200	-6%	-$947K	1.3%	13
2022 Q1	$16.8M	Buy	103,768 +11,900	+13%	+$1.73M	1.12%	13
2021 Q4	$12.4M	Sell	91,868 -5,700	-6%	-$673K	0.79%	26
2021 Q3	$10.5M	Sell	97,568 -4,400	-4%	-$503K	0.66%	29
2021 Q2	$11.5M	Buy	101,968 +7,200	+8%	+$811K	0.69%	29
2021 Q1	$10.3M	Buy	94,768 +23,350	+33%	+$2.5M	0.71%	29
2020 Q4	$7.65M	Buy	71,418 +10,500	+17%	+$1.01M	0.65%	33
2020 Q3	$5.34M	Sell	60,918 -1,800	-3%	-$169K	0.57%	39
2020 Q2	$6.16M	Buy	62,718 +13,971	+29%	+$1.23M	0.7%	31
2020 Q1	$3.71M	Buy	48,747 +4,500	+10%	+$383K	0.52%	44
2019 Q4	$3.92M	Sell	44,247 -5,600	-11%	-$465K	0.47%	54
2019 Q3	$3.77M	Sell	49,847 -12,200	-20%	-$836K	0.45%	56
2019 Q2	$4.51M	Buy	62,047 +2,200	+4%	+$173K	0.55%	41
2019 Q1	$4.82M	Buy	59,847 +1,400	+2%	+$115K	0.63%	36
2018 Q4	$5.39M	Hold	58,447	–	–	0.81%	25
2018 Q3	$5.53M	Sell	58,447 -22,300	-28%	-$2.11M	0.66%	31
2018 Q2	$7.48M	Buy	80,747 +2,600	+3%	+$254K	0.68%	28
2018 Q1	$7.4M	Hold	78,147	–	–	0.72%	27
2017 Q4	$7.56M	Sell	78,147 -10,300	-12%	-$971K	0.72%	27
2017 Q3	$7.86M	Hold	88,447	–	–	0.7%	30
2017 Q2	$6.41M	Hold	88,447	–	–	0.59%	36
2017 Q1	$5.76M	Sell	88,447 -61,300	-41%	-$3.85M	0.54%	44
2016 Q4	$9.38K	Buy	149,747 +8,630	+6%	+$527K	0.48%	41
2016 Q3	$5.97M	Sell	141,117 -67,630	-32%	-$4.38M	0.29%	75
2016 Q2	$12.9M	Buy	208,747 +10,000	+5%	+$609K	0.57%	38
2016 Q1	$11.4M	Hold	198,747	–	–	0.53%	40
2015 Q4	$11.8M	Buy	198,747 +8,200	+4%	+$472K	0.55%	42
2015 Q3	$10.4M	Hold	190,547	–	–	0.54%	38
2015 Q2	$12.8M	Buy	190,547 +16,765	+10%	+$1.09M	0.63%	33
2015 Q1	$10.2M	Sell	173,782 -9,300	-5%	-$562K	0.5%	43
2014 Q4	$12M	Sell	183,082 -51,000	-22%	-$3.22M	0.56%	34
2014 Q3	$13.5M	Sell	234,082 -25,100	-10%	-$1.39M	0.51%	37
2014 Q2	$14.6M	Buy	259,182 +7,500	+3%	+$393K	0.53%	37
2014 Q1	$12.9M	Buy	251,682 +230,282	+1,076%	+$11.6M	0.49%	40
2013 Q4	$1.13M	Sell	21,400 -3,500	-14%	-$172K	0.73%	48
2013 Q3	$1.11M	Hold	24,900	–	–	0.77%	40
2013 Q2	$1.03M	Buy	+24,900	New	+$1.09M	0.74%	39

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Livforsakringsbolaget Skandia's ABBV Position: Q1 2026 in Review

Livforsakringsbolaget Skandia increased its AbbVie (ABBV) stake by 14% in Q1 2026, buying an estimated $4.1M and bringing the position to 155,470 shares worth $33.8M. The position accounts for 1.31% of the portfolio, ranked #13.

Livforsakringsbolaget Skandia first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 4,090 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Livforsakringsbolaget Skandia held 155,470 shares of AbbVie worth $33.8M as of Q1 2026.
Livforsakringsbolaget Skandia bought 18,500 AbbVie shares in Q1 2026, an estimated $4.1M.
AbbVie made up 1.31% of Livforsakringsbolaget Skandia's portfolio in Q1 2026, its #13 holding.
Livforsakringsbolaget Skandia first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
4,090 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Livforsakringsbolaget Skandia's 13F filing for Q1 2026, filed 5 May 2026.